Parkinson's Disease, New England Journal of Medicine, vol.339, issue.16, pp.1130-1143, 1998. ,
The parkinson's complex: Parkinsonism is just the tip of the iceberg, Annals of Neurology, vol.59, issue.4, pp.591-596, 2006. ,
Parkinson's Disease, Neuron, vol.39, issue.6, pp.889-909, 2003. ,
Proteasome inhibition and Parkinson's disease modeling, Annals of Neurology, vol.60, issue.2, pp.260-264, 2006. ,
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease, Neuron, vol.90, issue.4, pp.675-691, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01348875
Disease modification and biomarker development in Parkinson disease, Neurology, vol.94, issue.11, pp.481-494, 2020. ,
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance, Journal of Neurochemistry, vol.139, issue.1, pp.59-74, 2016. ,
Genetic risk factors in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.9-20, 2018. ,
The Evolution of Genetics: Alzheimer?s and Parkinson?s Diseases, Neuron, vol.90, issue.6, pp.1154-1163, 2016. ,
The genetic architecture of mitochondrial dysfunction in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.21-37, 2018. ,
Finding the missing heritability of complex diseases, Nature, vol.461, issue.7265, pp.747-753, 2009. ,
Epidemiology of Parkinson's disease, Revue Neurologique, vol.172, issue.1, pp.14-26, 2016. ,
Professional exposure to pesticides and Parkinson disease, Annals of Neurology, vol.66, issue.4, pp.494-504, 2009. ,
Occupation and Risk of Parkinsonism, Archives of Neurology, vol.66, issue.9, pp.1106-1113, 2009. ,
Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies, Environment International, vol.46, pp.30-43, 2012. ,
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Annals of Neurology, vol.36, issue.5, pp.765-770, 1994. ,
PARKINSONISM DUE TO n-HEXANE EXPOSURE, The Lancet, vol.334, issue.8667, p.874, 1989. ,
Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study, The Lancet, vol.354, issue.9175, pp.281-286, 1999. ,
Parkinson's Disease, New England Journal of Medicine, vol.339, issue.16, pp.1130-1143, 1998. ,
The parkinson's complex: Parkinsonism is just the tip of the iceberg, Annals of Neurology, vol.59, issue.4, pp.591-596, 2006. ,
Parkinson's Disease, Neuron, vol.39, issue.6, pp.889-909, 2003. ,
Proteasome inhibition and Parkinson's disease modeling, Annals of Neurology, vol.60, issue.2, pp.260-264, 2006. ,
Understanding Dopaminergic Cell Death Pathways in Parkinson Disease, Neuron, vol.90, issue.4, pp.675-691, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01348875
Disease modification and biomarker development in Parkinson disease, Neurology, vol.94, issue.11, pp.481-494, 2020. ,
Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance, Journal of Neurochemistry, vol.139, issue.1, pp.59-74, 2016. ,
Genetic risk factors in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.9-20, 2018. ,
The Evolution of Genetics: Alzheimer?s and Parkinson?s Diseases, Neuron, vol.90, issue.6, pp.1154-1163, 2016. ,
The genetic architecture of mitochondrial dysfunction in Parkinson?s disease, Cell and Tissue Research, vol.373, issue.1, pp.21-37, 2018. ,
Finding the missing heritability of complex diseases, Nature, vol.461, issue.7265, pp.747-753, 2009. ,
Epidemiology of Parkinson's disease, Revue Neurologique, vol.172, issue.1, pp.14-26, 2016. ,
Professional exposure to pesticides and Parkinson disease, Annals of Neurology, vol.66, issue.4, pp.494-504, 2009. ,
Occupation and Risk of Parkinsonism, Archives of Neurology, vol.66, issue.9, pp.1106-1113, 2009. ,
Occupational exposure to pesticides and Parkinson's disease: A systematic review and meta-analysis of cohort studies, Environment International, vol.46, pp.30-43, 2012. ,
Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions, Annals of Neurology, vol.36, issue.5, pp.765-770, 1994. ,
PARKINSONISM DUE TO n-HEXANE EXPOSURE, The Lancet, vol.334, issue.8667, p.874, 1989. ,
Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study, The Lancet, vol.354, issue.9175, pp.281-286, 1999. ,
A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease, Annals of Neurology, vol.52, issue.3, pp.276-284, 2002. ,
Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin, Brain Research, vol.984, issue.1-2, pp.224-232, 2003. ,
Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis, Neurology, vol.74, issue.12, pp.995-1002, 2010. ,
Validation of the MDS clinical diagnostic criteria for Parkinson's disease, Movement Disorders, vol.33, issue.10, pp.1601-1608, 2018. ,
Validation of the MDS clinical diagnostic criteria for Parkinson's disease, Mov Disord, vol.33, pp.1601-1608, 2018. ,
Movement disorder society criteria for clinically established early Parkinson's disease, Movement Disorders, vol.33, issue.10, pp.1643-1646, 2018. ,
Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, Neurology, vol.82, issue.20, pp.1791-1797, 2014. ,
Can dopamine transporter imaging define early PD?, Nature Reviews Neurology, vol.10, issue.8, pp.432-433, 2014. ,
Predicting Motor Decline and Disability in Parkinson Disease, Archives of Neurology, vol.59, issue.11, p.1724, 2002. ,
Prognostic factors for the progression of Parkinson's disease: A systematic review, Movement Disorders, vol.22, issue.13, pp.1839-1851, 2007. ,
Reproducibility of data-driven Parkinson's disease subtypes for clinical research, Parkinsonism & Related Disorders, vol.56, pp.102-106, 2018. ,
The Parkinson?s Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures, Brain Communications, vol.2, issue.2, p.46, 2020. ,
Agespecific progression of nigrostriatal dysfunction in Parkinson's disease, Ann Neurol, vol.69, pp.803-813, 2011. ,
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY, Brain, vol.114, issue.5, pp.2283-2301, 1991. ,
Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlations, Journal of the Neurological Sciences, vol.20, issue.4, pp.415-455, 1973. ,
Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, vol.24, pp.197-211, 2003. ,
A clinicopathological study of subtypes in Parkinson's disease, Brain, vol.132, pp.2947-57, 2009. ,
From Prodromal to Overt Parkinson?s Disease: Towards a New Definition in the Year 2040, Journal of Parkinson's Disease, vol.8, issue.s1, pp.S19-S23, 2018. ,
Peripheral synuclein tissue markers: a step closer to Parkinson?s disease diagnosis: Figure 1, Brain, vol.138, issue.8, pp.2120-2122, 2015. ,
The prediagnostic phase of Parkinson's disease, J Neurol Neurosurg Psychiatry, vol.87, pp.871-879, 2016. ,
Longitudinal analyses of cerebrospinal fluid ?-Synuclein in prodromal and early Parkinson's disease, Mov Disord, vol.34, pp.1354-1364, 2019. ,
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, vol.136, pp.2419-2431, 2013. ,
Precision medicine for disease modification in Parkinson disease, Nat Rev Neurol, vol.13, pp.119-126, 2017. ,
Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen, J Neural Trans, vol.110, pp.517-536, 2003. ,
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations, Mov Disord, vol.33, pp.660-677, 2018. ,
Disease-modification" trials in Parkinson disease: target populations, endpoints and study design, Neurology, vol.72, issue.7, pp.51-58, 2009. ,
Rational drug discovery design approaches for treating Parkinson's disease, Expert Opin Drug Discov, vol.10, pp.713-741, 2015. ,
New perspectives on study designs for evaluating neuroprotection in Parkinson's disease, Movement Disorders, vol.32, issue.10, pp.1365-1370, 2017. ,
Quantitative MRI markers in Parkinson's disease and parkinsonian syndromes, Current Opinion in Neurology, vol.33, issue.2, pp.222-229, 2020. ,
Assessment of the progression of Parkinson's disease: a metabolic network approach, The Lancet Neurology, vol.6, issue.10, pp.926-932, 2007. ,
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease, JAMA Neurol, vol.72, pp.100-105, 2015. ,
Disentangling the Relationship between Lewy Bodies and Nigral Neuronal Loss in Parkinson's Disease, Journal of Parkinson's Disease, vol.1, issue.3, pp.277-286, 2011. ,
Degeneration of dopaminergic circuitry influences depressive symptoms in Lewy body disorders, Brain Pathology, vol.29, pp.544-557, 2019. ,
Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis, Lancet Neurol, vol.16, pp.55-65, 2017. ,
Progressive parkinsonism in older adults is related to the burden of mixed brain pathologies, Neurology, vol.92, issue.16, pp.e1821-e1830, 2019. ,
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities, Translational Neurodegeneration, vol.8, issue.1, p.28, 2019. ,
Author response: Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases, Neurology, vol.94, issue.3, pp.144-145, 2020. ,
Oncogene-induced senescence and tumour control in complex biological systems, Cell Death & Differentiation, vol.25, issue.6, pp.1005-1006, 2018. ,
Ferroptosis, a newly characterized form of cell death in Parkinson's disease that is regulated by PKC, Neurobiol Dis, vol.94, pp.169-78, 2016. ,
Ferroptosis and cell death mechanisms in Parkinson's disease, Neurochemistry International, vol.104, pp.34-48, 2017. ,
Poly(ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson?s disease, Science, vol.362, issue.6414, p.eaat8407, 2018. ,
ADP-ribose) drives pathologic ?-synuclein neurodegeneration in Parkinson's disease, Science, vol.362, issue.6414, p.8407, 2018. ,
Chaperone-mediated autophagy is involved in the execution of ferroptosis, Proceedings of the National Academy of Sciences, vol.116, issue.8, pp.2996-3005, 2019. ,
Interplay between MTOR and GPX4 signaling modulates autophagy-dependent ferroptotic cancer cell death, Cancer Gene Therapy, 2020. ,
Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease, Journal of Neurochemistry, vol.86, issue.5, pp.1297-1307, 2003. ,
Targets for neuroprotection in Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1792, issue.7, pp.676-687, 2009. ,
In vitro Models of Neurodegenerative Diseases, Frontiers in Cell and Developmental Biology, vol.8, p.328, 2020. ,
Animal models for preclinical Parkinson's research: An update and critical appraisal, Progress in Brain Research, vol.252, pp.27-59, 2020. ,
Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long term losses of dopamine neurons in offspring a potential new model of parkinson s disease, Frontiers in Bioscience, vol.8, issue.6, pp.s826-837, 2003. ,
Age, experience, injury, and the changing brain, Developmental Psychobiology, vol.54, issue.3, pp.311-325, 2010. ,
Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols, Trials, vol.20, issue.1, p.572, 2019. ,
Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson?s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer, Journal of Parkinson's Disease, vol.10, issue.2, pp.413-428, 2020. ,
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics, Movement Disorders, vol.23, issue.15, pp.2194-2201, 2008. ,
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson?s disease, npj Parkinson's Disease, vol.4, issue.1, p.14, 2018. ,
Blood vessels change in the mesencephalon of patients with Parkinson's disease, The Lancet, vol.353, issue.9157, pp.981-982, 1999. ,
Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian, Journal of Neural Transmission, vol.112, issue.9, pp.1237-1248, 2005. ,
Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease, NeuroImage, vol.61, issue.1, pp.228-239, 2012. ,
Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies, Journal of Controlled Release, vol.270, pp.89-100, 2018. ,
Synthesis and characterization of brain penetrant prodrug of neuroprotective D-264: Potential therapeutic application in the treatment of Parkinson?s disease, European Journal of Pharmaceutics and Biopharmaceutics, vol.103, pp.62-70, 2016. ,
Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood?Brain Barrier, Pharmaceutics, vol.6, issue.4, pp.557-583, 2014. ,
Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury, Nature Nanotechnology, vol.9, issue.12, pp.1054-1062, 2014. ,
N-Acetylcysteine Nanocarriers Protect against Oxidative Stress in a Cellular Model of Parkinson?s Disease, Antioxidants, vol.9, issue.7, p.600, 2020. ,
Towards Improvements for Penetrating the Blood?Brain Barrier?Recent Progress from a Material and Pharmaceutical Perspective, Cells, vol.7, issue.4, p.24, 2018. ,
Intrathecal baclofen for treating spasticity in children with cerebral palsy, Cochrane Database of Systematic Reviews, vol.11, p.4552, 2015. ,
Safety and tolerability of intracerebroventricular PDGF-BB in Parkinson?s disease patients, Journal of Clinical Investigation, vol.125, issue.3, pp.1339-1346, 2015. ,
Focused ultrasound-mediated drug delivery through the blood?brain barrier, Expert Review of Neurotherapeutics, vol.15, issue.5, pp.477-491, 2015. ,
,
Transcranial Photoacoustic Detection of Blood-Brain Barrier Disruption Following Focused Ultrasound-Mediated Nanoparticle Delivery, Molecular Imaging and Biology, vol.22, issue.2, pp.324-334, 2019. ,
Key factors in the rising cost of new drug discovery and development, Nature Reviews Drug Discovery, vol.3, issue.5, pp.417-429, 2004. ,
Targeting Chelatable Iron as a Therapeutic Modality in Parkinson's Disease, Antioxidants & Redox Signaling, vol.21, issue.2, pp.195-210, 2014. ,
Iron as a therapeutic target for Parkinson's disease, Movement Disorders, vol.33, issue.4, pp.568-574, 2018. ,
, Mov Disord, vol.33, pp.568-574, 2018.
Parkinson's disease drug therapies in the clinical trial pipeline: 2020, J Parkinsons Dis, vol.10, pp.757-774, 2020. ,